130 related articles for article (PubMed ID: 25388794)
1. Unusual presentation of advanced prostate cancer masquerading as metastatic and obstructing rectosigmoid cancer.
Chang MD; Davidson AJ; Sutherland T; De Fontgalland D; Johnson D; Wong LM
ANZ J Surg; 2017 May; 87(5):417-419. PubMed ID: 25388794
[No Abstract] [Full Text] [Related]
2. Separate annular strictures of the rectosigmoid colon secondary to unsuspected prostate cancer.
Culkin DJ; Demos TC; Wheeler JS; Castelli M; Canning JR
J Surg Oncol; 1990 Mar; 43(3):189-92. PubMed ID: 2314106
[TBL] [Abstract][Full Text] [Related]
3. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
4. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
5. Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Kanesvaran R; Phipps C; Cheng CW; Chan MM; Khoo D; Tan MH
Ann Acad Med Singap; 2010 Jul; 39(7):580-2. PubMed ID: 20697679
[No Abstract] [Full Text] [Related]
6. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
7. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
8. Paraneoplastic jaundice and prostate cancer.
Vieira AC; Alvarenga MJ; Santos JC; Silva AM
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28433972
[TBL] [Abstract][Full Text] [Related]
9. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
10. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A; Penson D; Dewilde S; Kleinman L
Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
[TBL] [Abstract][Full Text] [Related]
11. Bicalutamide with radiotherapy for prostate cancer.
Brower V
Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
[No Abstract] [Full Text] [Related]
12. [Prostate cancer - androgen deprivation: intermittent or continuous?].
Wedel SA
Aktuelle Urol; 2014 May; 45(3):180-1. PubMed ID: 24932555
[No Abstract] [Full Text] [Related]
13. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Taneja SS
J Urol; 2013 Dec; 190(6):2093-4. PubMed ID: 24209518
[No Abstract] [Full Text] [Related]
14. Adenocarcinoma of the prostate presenting as an obstructing rectal mass.
Boland PM; Dhillon RS; Goldstein SD; O'hara BJ; Kastenberg DM
Dig Dis Sci; 2007 Oct; 52(10):2800-5. PubMed ID: 17443413
[No Abstract] [Full Text] [Related]
15. Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.
Yano A; Kagawa M; Takeshita H; Okada Y; Morozumi M; Kawakami S
Int J Urol; 2017 Dec; 24(12):861-862. PubMed ID: 28895205
[No Abstract] [Full Text] [Related]
16. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
Wadhwa VK; Weston R; Parr NJ
BJU Int; 2011 Jun; 107(12):1923-9. PubMed ID: 20950306
[TBL] [Abstract][Full Text] [Related]
18. Words of wisdom. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Sciarra A
Eur Urol; 2013 Dec; 64(6):1014-5. PubMed ID: 24209449
[No Abstract] [Full Text] [Related]
19. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
Molenaar JP; Baten A; Blokx WA; Hoogendam A
Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
[TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more.
Fui MN; Grossmann M
Asian J Androl; 2013 Jul; 15(4):445-6. PubMed ID: 23685907
[No Abstract] [Full Text] [Related]
[Next] [New Search]
